Professors, Matthew Macauley and John Klassen, from the University of Alberta are investigating how glycomics, the study of carbohydrates (sugars) may be linked to Alzheimer’s disease. Determining how the glycans (sugars) interact with a protein known as CD33, which has strong implications in Alzheimer’s disease, may create potential therapies. The researchers explain that receptors for sugars in microglia (white blood cells found in the brain) can serve as an indicator of who will develop Alzheimer’s disease. Different isoforms of these carbohydrate receptors have been found to have protective effects against Alzheimer’s disease. This research takes a completely different approach than most Alzheimer’s research and may be transformative, not just for Alzheimer’s but for many other diseases. "This is exactly the kind of research that we hope will translate into tangible benefits for people worldwide," says Todd Lowary, Scientific Director, GlycoNet. GlycoNet has given a grant to 11 different researchers across Canada to study different aspect of research, the grants total to $1.6 million.
Date Retrieved: February 9th 2018